Morepen Laboratories expects revenues and net to rise by $20 million (Rs 1000 million) and $10-12 million (Rs 500-600 million) respectively, enhanced by a 180-day marketing exclusivity granted to Geneva Pharmaceuticals Inc for Loratadine in the U S.

Morepen is the sole supplier for bulk Loratadine to Geneva Pharma, an arm of Novartis AG. Geneva Pharma already launched its generic version of Claritin in the US market.

BSE Code: 500288